Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Crizocent 250 mg
Crizotinib 250mg capsules – Incepta Pharmaceuticals Ltd.
Indicated for adults with metastatic ALK-positive NSCLC and for metastatic ROS1-positive NSCLC — the first FDA-approved biomarker-driven therapy for both ALK-positive and ROS1-positive metastatic NSCLC, and the only FDA-approved drug specifically for ROS1-positive NSCLC.
- Clinical outcomes at a glance
1st
FDA-approved biomarker-driven therapy for ALK-positive NSCLC — established the entire ALK inhibitor treatment class
Only
FDA-approved drug specifically indicated for ROS1-positive metastatic NSCLC — a unique, distinct approval
~72%
Overall response rate in ROS1-positive NSCLC (PROFILE 1001 trial), with median duration of response exceeding 17 months
Context
Superseded by second- and third-generation ALK inhibitors in first-line ALK+ NSCLC — clinical positioning matters
- Am I a candidate? — Take Decesion
1
Confirm ALK or ROS1 status via FDA-approved test
ALK or ROS1 rearrangement must be confirmed using an FDA-approved diagnostic test on tumor tissue. If being considered for ALK-positive NSCLC, discuss whether a newer-generation ALK inhibitor (alectinib, brigatinib) is more appropriate as first-line therapy.
2
Baseline ophthalmologic assessment — vision disorders are the most common side effect
Vision disorders occur in over 60% of patients — baseline vision assessment helps distinguish pre-existing issues from drug-related changes, and new or worsening visual symptoms should be reported promptly throughout treatment.
3
Baseline liver function and cardiac assessment
Hepatotoxicity requiring dose modification has occurred — baseline liver function tests are essential. QT prolongation and bradycardia have been reported; baseline ECG and electrolyte assessment is recommended in predisposed patients.
4
Review kidney function and drug interactions
Severe renal impairment requires once-daily dosing. Strong CYP3A inhibitors and inducers, as well as CYP3A substrates with narrow therapeutic indices, should be avoided — a complete medication review is essential before starting.
Important safety information: Hepatotoxicity — liver function should be monitored periodically; dose reduction, interruption, or permanent discontinuation may be required. Interstitial lung disease/pneumonitis can be severe and fatal — permanently discontinue if ILD/pneumonitis is diagnosed. QT interval prolongation has been reported — monitor with ECG and electrolytes in predisposed patients. Bradycardia can occur — monitor heart rate and blood pressure. Embryo-fetal toxicity — effective contraception required during treatment and for at least 45 days after the final dose for females; males should use contraception during and for at least 90 days after the final dose.
- common side effects to know
- Vision disorders (most common, >60%)
- Nausea / vomiting / diarrhea
- Edema / constipation / fatigue
- Decreased appetite / dizziness / neuropathy
- Hepatotoxicity / ILD / pneumonitis
- QT prolongation / bradycardia
- Trust & expertise
- FDA Approved 2011 (ALK) & 2016 (ROS1)
- EMA Approved 2012
- NCCN NSCLC Guidelines
- PROFILE 1001 / 1005 / 1007 / 1014 Trials
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Crizotinib was a landmark drug — the first proof that targeting ALK specifically could dramatically outperform chemotherapy in a biomarker-selected lung cancer population. Today, second- and third-generation ALK inhibitors have largely superseded it in first-line ALK-positive NSCLC based on superior efficacy and better CNS penetration. But crizotinib remains uniquely important as the only FDA-approved agent for ROS1-positive NSCLC, a population without the same breadth of newer targeted options yet available.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
We covered this in full detail just a few pages back for the Crizonix page — here’s the complete set pulled forward rather than repeating the research.
Before confirming crizotinib as your treatment
- Is my tumor ALK-positive, ROS1-positive, or both — and which is the primary reason for prescribing crizotinib?
- If I’m ALK-positive, why is crizotinib being recommended rather than a newer-generation ALK inhibitor like alectinib or brigatinib, which have shown superior progression-free survival and better brain penetration in head-to-head trials?
- If I’m ROS1-positive, is crizotinib being recommended because it’s currently the only FDA-approved option for this specific rearrangement?
- Has my tumor been tested for other driver mutations like EGFR or MET amplification?
- Are there clinical trials I should know about?
About vision disorders — the most common side effect
- What types of visual symptoms should I report, and when does a vision change need urgent evaluation versus routine follow-up?
- Should I have a baseline ophthalmologic assessment before starting?
- Are there activities — driving at night, precision work — I should be cautious about while visual symptoms occur?
About liver monitoring
- Will my liver function be checked at baseline and periodically?
- What symptoms — yellowing of skin or eyes, dark urine, severe fatigue, abdominal pain — should prompt an urgent call?
About lung monitoring
- What symptoms of ILD or pneumonitis — new shortness of breath, cough, fever — should prompt immediate evaluation?
- How will we distinguish drug-related lung changes from disease-related ones?
About cardiac monitoring
- Will I have a baseline ECG given the QT prolongation risk?
- Are there other medications I take that compound this risk?
- What symptoms of bradycardia — dizziness, fainting, unusual slowness of heartbeat — should prompt urgent care?
About kidney function and dosing
- What is my current creatinine clearance, and does it require dose reduction to once daily?
About dosing and administration
- The dose is 250mg twice daily — should doses be taken at consistent times, and does food matter?
- What should I do if I miss a dose?
- Should capsules always be swallowed whole?
About managing common side effects
- Nausea, vomiting, diarrhea, and constipation seem very common — is there anything I can do proactively to manage these?
- Are there activity precautions given the dizziness and neuropathy that can occur?
About drug interactions
- Are there strong CYP3A inhibitors or inducers I should avoid or that require dose adjustment?
- Should I avoid grapefruit?
- If I’m prescribed something new by another doctor, what should they know?
About contraception
- What contraception is required, and for how long after the final dose — noting the windows differ for females (45 days) and males (90 days)?
About monitoring response and the longer road
- What imaging schedule will track whether this is working?
- Given crizotinib’s known CNS limitations, will brain imaging be part of my monitoring schedule?
- If crizotinib stops working, what would typically be considered next — particularly for my specific rearrangement?
- Are there patient assistance programs available if cost is a concern?
A practical tip: The single most important question to ask — particularly if you’re ALK-positive — is why crizotinib specifically rather than a newer-generation ALK inhibitor, since the head-to-head trial evidence favoring alectinib and brigatinib over crizotinib in first-line ALK-positive NSCLC is among the clearest in this drug class. For ROS1-positive disease, the answer is straightforward since crizotinib is the only approved option, but for ALK-positive patients the reasoning deserves a direct, explicit answer from your oncologist.
compare with other therapies
We covered this comparison in full detail just a few pages back — here’s the key findings pulled forward concisely.
The ALEX trial — a decisive head-to-head result
This comparison has one of the clearest outcomes in our series. The ALEX trial directly compared alectinib versus crizotinib as first-line therapy in previously untreated ALK-positive metastatic NSCLC, and the result was unambiguous: alectinib demonstrated more than three times the progression-free survival (34.8 months versus 10.9 months with crizotinib), along with dramatically better CNS control, confirmed overall survival benefit in longer-term follow-up, and a more favorable side-effect profile.
The CNS finding is as important as the PFS numbers
ALK-positive NSCLC has a notably high rate of brain metastases, making CNS control one of the most critical treatment goals in this cancer. CNS progression occurred in only 12% of alectinib-treated patients versus 45% with crizotinib — more than a threefold difference. Crizotinib’s poor blood-brain barrier penetration was a well-recognized limitation of the first-generation drug; alectinib was specifically engineered to address this, and the ALEX trial confirmed it prospectively.
Side effects also favor alectinib
Alectinib’s side-effect pattern — anemia, elevated bilirubin, peripheral edema — is generally considered more manageable than crizotinib’s distinctively high rate of vision disorders (occurring in over 60% of patients), nausea, vomiting, and the QT prolongation and bradycardia risks that require more intensive cardiac monitoring.
Where crizotinib still has a role
Given these results, crizotinib is no longer the preferred first-line option at most major cancer centers for ALK-positive NSCLC when alectinib (or brigatinib, or lorlatinib) are available. However, crizotinib remains genuinely relevant in specific circumstances:
For ROS1-positive NSCLC specifically, crizotinib remains the only FDA-approved targeted option — alectinib wasn’t developed for this separate rearrangement.
Access and cost — crizotinib’s generic availability in Bangladesh and other markets makes it substantially more accessible in price-sensitive settings than branded newer-generation agents.
Post-progression sequencing — patients who progressed on crizotinib can still respond to alectinib or brigatinib, since these drugs were specifically designed to overcome the resistance mutations that develop against crizotinib.
Bottom line
Alectinib comprehensively outperformed crizotinib in the ALEX head-to-head trial across every major efficacy and most safety measures. For ALK-positive NSCLC, second-generation agents have replaced crizotinib as the preferred first-line approach in guidelines and standard practice. Crizotinib’s ongoing value in ALK-positive disease is primarily in settings where newer agents aren’t accessible, or as part of a sequenced approach — and its unique position in ROS1-positive disease remains separately important and unreplaced.
How does testing work
We covered this in full detail just a few pages back — here’s the key explanation pulled forward rather than repeating the research.
What ROS1 is and what makes a tumor “ROS1-positive”
ROS1 is a receptor tyrosine kinase that in normal adult tissue is expressed at relatively low levels with a poorly understood physiological role. In approximately 1-2% of NSCLC cases, a chromosomal rearrangement fuses the ROS1 gene to a partner gene — most commonly CD74 — creating an abnormal fusion protein that behaves like a permanently switched-on kinase, continuously driving cell proliferation and survival signals regardless of normal regulatory input. This makes ROS1-positive NSCLC an “oncogene-addicted” cancer, heavily dependent on this single abnormal kinase for growth and survival — precisely the kind of specific molecular vulnerability that targeted therapy is designed to exploit.
Why ROS1-positive disease resembles but differs from ALK-positive disease
ROS1-positive and ALK-positive NSCLC share several clinical features — both tend to occur in younger patients, more often non-smokers or light smokers, more commonly in adenocarcinoma histology. This demographic overlap reflects their shared status as oncogene-driven cancers in patients without heavy carcinogen exposure. But they arise from different genes, develop different acquired resistance patterns, and currently have very different targeted therapy landscapes — the ALK field has progressed through three generations of inhibitors, while the ROS1 field has considerably fewer approved, well-validated options.
Why crizotinib works against ROS1-positive tumors
The ROS1 kinase domain is structurally highly similar to the ALK kinase domain — so similar that drugs designed to block ALK also block ROS1 with meaningful potency. This structural overlap is why crizotinib, originally developed for ALK-positive NSCLC, showed substantial activity in ROS1-positive disease, earning its separate FDA approval for that indication in 2016. By binding to and blocking the ROS1 fusion protein’s kinase domain, crizotinib shuts off the constitutive growth signal the tumor depends on.
How well it works
The PROFILE 1001 trial’s ROS1-positive cohort showed an overall response rate of approximately 72%, with median duration of response exceeding 17 months — substantially better than chemotherapy, reflecting the same principle seen throughout this conversation: precisely matching a targeted drug to the molecular driver of a patient’s cancer produces dramatically better results than treating all patients identically.
The CNS limitation in ROS1-positive disease
Crizotinib has limited blood-brain barrier penetration, allowing brain metastases to develop even in patients whose systemic disease responds well. In ALK-positive NSCLC this problem has been substantially addressed by second-generation drugs. In ROS1-positive NSCLC the targeted therapy landscape is considerably less developed, making crizotinib’s CNS limitation a more ongoing practical challenge than in the ALK-positive setting.
What comes after crizotinib in ROS1-positive disease
Options after crizotinib progression in ROS1-positive NSCLC are less clearly defined than in ALK-positive disease. Lorlatinib has shown activity in some ROS1-positive patients who progressed on crizotinib. Entrectinib, approved for both ROS1-positive NSCLC and NTRK-fusion positive tumors, also covers this indication with better CNS penetration than crizotinib. But the overall landscape of approved, well-validated post-crizotinib options in ROS1-positive disease remains more limited than what ALK-positive patients have access to.
The bigger picture
Crizotinib’s unique position as the only FDA-approved drug specifically for ROS1-positive NSCLC — rather than simply a first-generation option that has been superseded — reflects both the structural overlap between ROS1 and ALK that made the drug effective here, and the reality that the ROS1-positive population hasn’t yet attracted the same depth of competitive drug development that produced the impressive ALK inhibitor options we’ve covered throughout this conversation.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
